{
  "title": "Optimizing human α-galactosidase for treatment of Fabry disease",
  "year": 2023,
  "authors": [
    "William C. Hallows",
    "Kristen Skvorak",
    "Nick Agard",
    "Nikki Kruse",
    "Xiyun Zhang",
    "Yu Zhu",
    "Rachel C. Botham",
    "Chinping Chng",
    "Charu Shukla",
    "Jessica Lao",
    "Mathew Miller",
    "Antoinette Sero",
    "Judy Viduya",
    "Moulay Hicham Alaoui Ismaili",
    "Kerryn McCluskie",
    "Raphael Schiffmann",
    "Adam P. Silverman",
    "Jin-Song Shen",
    "Gjalt W. Huisman"
  ],
  "journal": "Sci Rep",
  "crossref": {
    "indexed": {
      "date-parts": [
        [
          2025,
          8,
          6
        ]
      ],
      "date-time": "2025-08-06T12:48:55Z",
      "timestamp": 1754484535752
    },
    "reference-count": 70,
    "publisher": "Springer Science and Business Media LLC",
    "issue": "1",
    "license": [
      {
        "start": {
          "date-parts": [
            [
              2023,
              3,
              23
            ]
          ],
          "date-time": "2023-03-23T00:00:00Z",
          "timestamp": 1679529600000
        },
        "content-version": "tdm",
        "delay-in-days": 0,
        "URL": "https://creativecommons.org/licenses/by/4.0"
      },
      {
        "start": {
          "date-parts": [
            [
              2023,
              3,
              23
            ]
          ],
          "date-time": "2023-03-23T00:00:00Z",
          "timestamp": 1679529600000
        },
        "content-version": "vor",
        "delay-in-days": 0,
        "URL": "https://creativecommons.org/licenses/by/4.0"
      }
    ],
    "content-domain": {
      "domain": [
        "link.springer.com"
      ],
      "crossmark-restriction": false
    },
    "short-container-title": [
      "Sci Rep"
    ],
    "abstract": "<jats:title>Abstract</jats:title><jats:p>Fabry disease is caused by a deficiency of α-galactosidase A (GLA) leading to the lysosomal accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids. Fabry patients experience significant damage to the heart, kidney, and blood vessels that can be fatal. Here we apply directed evolution to generate more stable GLA variants as potential next generation treatments for Fabry disease. GLAv05 and GLAv09 were identified after screening more than 12,000 GLA variants through 8 rounds of directed evolution. Both GLAv05 and GLAv09 exhibit increased stability at both lysosomal and blood pH, stability to serum, and elevated enzyme activity in treated Fabry fibroblasts (19-fold) and GLA<jats:sup>–/–</jats:sup>podocytes (10-fold). GLAv05 and GLAv09 show improved pharmacokinetics in mouse and non-human primates. In a Fabry mouse model, the optimized variants showed prolonged half-lives in serum and relevant tissues, and a decrease of accumulated Gb3 in heart and kidney. To explore the possibility of diminishing the immunogenic potential of rhGLA, amino acid residues in sequences predicted to bind MHC II were targeted in late rounds of GLAv09 directed evolution. An MHC II-associated peptide proteomics assay confirmed a reduction in displayed peptides for GLAv09. Collectively, our findings highlight the promise of using directed evolution to generate enzyme variants for more effective treatment of lysosomal storage diseases.</jats:p>",
    "DOI": "10.1038/s41598-023-31777-4",
    "type": "journal-article",
    "created": {
      "date-parts": [
        [
          2023,
          3,
          23
        ]
      ],
      "date-time": "2023-03-23T10:02:48Z",
      "timestamp": 1679565768000
    },
    "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
    "source": "Crossref",
    "is-referenced-by-count": 11,
    "title": [
      "Optimizing human α-galactosidase for treatment of Fabry disease"
    ],
    "prefix": "10.1038",
    "volume": "13",
    "author": [
      {
        "given": "William C.",
        "family": "Hallows",
        "sequence": "first",
        "affiliation": []
      },
      {
        "given": "Kristen",
        "family": "Skvorak",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Nick",
        "family": "Agard",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Nikki",
        "family": "Kruse",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Xiyun",
        "family": "Zhang",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Yu",
        "family": "Zhu",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Rachel C.",
        "family": "Botham",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Chinping",
        "family": "Chng",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Charu",
        "family": "Shukla",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Jessica",
        "family": "Lao",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Mathew",
        "family": "Miller",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Antoinette",
        "family": "Sero",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Judy",
        "family": "Viduya",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Moulay Hicham Alaoui",
        "family": "Ismaili",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Kerryn",
        "family": "McCluskie",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Raphael",
        "family": "Schiffmann",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Adam P.",
        "family": "Silverman",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Jin-Song",
        "family": "Shen",
        "sequence": "additional",
        "affiliation": []
      },
      {
        "given": "Gjalt W.",
        "family": "Huisman",
        "sequence": "additional",
        "affiliation": []
      }
    ],
    "member": "297",
    "published-online": {
      "date-parts": [
        [
          2023,
          3,
          23
        ]
      ]
    },
    "reference": [
      {
        "key": "31777_CR1",
        "doi-asserted-by": "publisher",
        "first-page": "231",
        "DOI": "10.1016/B978-0-444-62702-5.00017-2",
        "volume": "132",
        "author": "R Schiffmann",
        "year": "2015",
        "unstructured": "Schiffmann, R. Fabry disease. Handb. Clin. Neurol. 132, 231–248 (2015).",
        "journal-title": "Handb. Clin. Neurol."
      },
      {
        "issue": "6",
        "key": "31777_CR2",
        "doi-asserted-by": "publisher",
        "first-page": "425",
        "DOI": "10.7326/0003-4819-146-6-200703200-00007",
        "volume": "146",
        "author": "JT Clarke",
        "year": "2007",
        "unstructured": "Clarke, J. T. Narrative review: Fabry disease. Ann. Intern. Med. 146(6), 425–433 (2007).",
        "journal-title": "Ann. Intern. Med."
      },
      {
        "key": "31777_CR3",
        "doi-asserted-by": "publisher",
        "first-page": "10",
        "DOI": "10.1016/j.pediatrneurol.2016.07.001",
        "volume": "64",
        "author": "R Schiffmann",
        "year": "2016",
        "unstructured": "Schiffmann, R. & Ries, M. Fabry disease: A disorder of childhood onset. Pediatr. Neurol. 64, 10–20 (2016).",
        "journal-title": "Pediatr. Neurol."
      },
      {
        "issue": "1",
        "key": "31777_CR4",
        "doi-asserted-by": "publisher",
        "first-page": "31",
        "DOI": "10.1086/504601",
        "volume": "79",
        "author": "M Spada",
        "year": "2006",
        "unstructured": "Spada, M. et al. High incidence of later-onset fabry disease revealed by newborn screening. Am. J. Hum. Genet. 79(1), 31–40 (2006).",
        "journal-title": "Am. J. Hum. Genet."
      },
      {
        "issue": "3",
        "key": "31777_CR5",
        "doi-asserted-by": "crossref",
        "first-page": "534",
        "DOI": "10.1002/jimd.12080",
        "volume": "42",
        "author": "R Schiffmann",
        "year": "2019",
        "unstructured": "Schiffmann, R. et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial. J. Inherit. Metab. Dis. 42(3), 534–544 (2019).",
        "journal-title": "J. Inherit. Metab. Dis."
      },
      {
        "issue": "3",
        "key": "31777_CR6",
        "doi-asserted-by": "publisher",
        "first-page": "527",
        "DOI": "10.1002/jimd.12052",
        "volume": "42",
        "author": "JB Hennermann",
        "year": "2019",
        "unstructured": "Hennermann, J. B. et al. Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease. J. Inherit. Metab. Dis. 42(3), 527–533 (2019).",
        "journal-title": "J. Inherit. Metab. Dis."
      },
      {
        "issue": "3",
        "key": "31777_CR7",
        "doi-asserted-by": "publisher",
        "first-page": "431",
        "DOI": "10.1007/s00228-019-02808-9",
        "volume": "76",
        "author": "ML Boof",
        "year": "2020",
        "unstructured": "Boof, M. L. et al. Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects. Eur. J. Clin. Pharmacol. 76(3), 431–437 (2020).",
        "journal-title": "Eur. J. Clin. Pharmacol."
      },
      {
        "issue": "1",
        "key": "31777_CR8",
        "doi-asserted-by": "publisher",
        "first-page": "1178",
        "DOI": "10.1038/s41467-021-21371-5",
        "volume": "12",
        "author": "A Khan",
        "year": "2021",
        "unstructured": "Khan, A. et al. Lentivirus-mediated gene therapy for Fabry disease. Nat. Commun. 12(1), 1178 (2021).",
        "journal-title": "Nat. Commun."
      },
      {
        "key": "31777_CR9",
        "unstructured": "ClinicalTrails.gov, Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease; Identifier NCT02800070. 2020, Bethesda (MD): National Library of Medicine (US)."
      },
      {
        "issue": "4",
        "key": "31777_CR10",
        "doi-asserted-by": "publisher",
        "first-page": "407",
        "DOI": "10.1016/j.ekir.2019.11.013",
        "volume": "5",
        "author": "A Felis",
        "year": "2020",
        "unstructured": "Felis, A. et al. Current and Investigational Therapeutics for Fabry Disease. Kidney Int. Rep. 5(4), 407–413 (2020).",
        "journal-title": "Kidney Int. Rep."
      },
      {
        "key": "31777_CR11",
        "doi-asserted-by": "publisher",
        "first-page": "29",
        "DOI": "10.1186/1750-1172-8-29",
        "volume": "8",
        "author": "SM Rombach",
        "year": "2013",
        "unstructured": "Rombach, S. M. et al. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet. J. Rare Dis. 8, 29 (2013).",
        "journal-title": "Orphanet. J. Rare Dis."
      },
      {
        "key": "31777_CR12",
        "doi-asserted-by": "publisher",
        "first-page": "77",
        "DOI": "10.1186/s13023-015-0296-8",
        "volume": "10",
        "author": "M Arends",
        "year": "2015",
        "unstructured": "Arends, M., Hollak, C. E. & Biegstraaten, M. Quality of life in patients with Fabry disease: A systematic review of the literature. Orphanet. J. Rare Dis. 10, 77 (2015).",
        "journal-title": "Orphanet. J. Rare Dis."
      },
      {
        "issue": "3",
        "key": "31777_CR13",
        "doi-asserted-by": "publisher",
        "first-page": "212",
        "DOI": "10.1016/j.ymgme.2018.04.007",
        "volume": "126",
        "author": "M Spada",
        "year": "2019",
        "unstructured": "Spada, M. et al. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease—a systematic literature review by a European panel of experts. Mol. Genet. Metab. 126(3), 212–223 (2019).",
        "journal-title": "Mol. Genet. Metab."
      },
      {
        "key": "31777_CR14",
        "doi-asserted-by": "publisher",
        "first-page": "100454",
        "DOI": "10.1016/j.ymgmr.2019.100454",
        "volume": "19",
        "author": "DP Germain",
        "year": "2019",
        "unstructured": "Germain, D. P. et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol. Genet. Metab. Rep. 19, 100454 (2019).",
        "journal-title": "Mol. Genet. Metab. Rep."
      },
      {
        "issue": "3",
        "key": "31777_CR15",
        "doi-asserted-by": "publisher",
        "first-page": "224",
        "DOI": "10.1016/j.ymgme.2018.09.007",
        "volume": "126",
        "author": "DP Germain",
        "year": "2019",
        "unstructured": "Germain, D. P. et al. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease—a systematic literature review by a European panel of experts. Mol. Genet. Metab. 126(3), 224–235 (2019).",
        "journal-title": "Mol. Genet. Metab."
      },
      {
        "issue": "9",
        "key": "31777_CR16",
        "doi-asserted-by": "publisher",
        "first-page": "2265",
        "DOI": "10.1681/ASN.2018030329",
        "volume": "29",
        "author": "M Lenders",
        "year": "2018",
        "unstructured": "Lenders, M. & Brand, E. Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. J. Am. Soc. Nephrol. 29(9), 2265–2278 (2018).",
        "journal-title": "J. Am. Soc. Nephrol."
      },
      {
        "issue": "2",
        "key": "31777_CR17",
        "doi-asserted-by": "publisher",
        "first-page": "66",
        "DOI": "10.1016/j.ymgme.2015.11.001",
        "volume": "117",
        "author": "PS Kishnani",
        "year": "2016",
        "unstructured": "Kishnani, P. S. et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol. Genet. Metab. 117(2), 66–83 (2016).",
        "journal-title": "Mol. Genet. Metab."
      },
      {
        "issue": "1",
        "key": "31777_CR18",
        "doi-asserted-by": "publisher",
        "first-page": "256",
        "DOI": "10.1681/ASN.2014121226",
        "volume": "27",
        "author": "M Lenders",
        "year": "2016",
        "unstructured": "Lenders, M. et al. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J. Am. Soc. Nephrol. 27(1), 256–264 (2016).",
        "journal-title": "J. Am. Soc. Nephrol."
      },
      {
        "issue": "10",
        "key": "31777_CR19",
        "doi-asserted-by": "publisher",
        "first-page": "e47805",
        "DOI": "10.1371/journal.pone.0047805",
        "volume": "7",
        "author": "SM Rombach",
        "year": "2012",
        "unstructured": "Rombach, S. M. et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 7(10), e47805 (2012).",
        "journal-title": "PLoS One"
      },
      {
        "issue": "1118",
        "key": "31777_CR20",
        "doi-asserted-by": "publisher",
        "first-page": "709",
        "DOI": "10.1136/postgradmedj-2018-136056",
        "volume": "94",
        "author": "T Cairns",
        "year": "2018",
        "unstructured": "Cairns, T. et al. Hot topics in Fabry disease. Postgrad. Med. J. 94(1118), 709–713 (2018).",
        "journal-title": "Postgrad. Med. J."
      },
      {
        "issue": "17",
        "key": "31777_CR21",
        "doi-asserted-by": "publisher",
        "first-page": "1969",
        "DOI": "10.1007/s40265-021-01621-y",
        "volume": "81",
        "author": "M Lenders",
        "year": "2021",
        "unstructured": "Lenders, M. & Brand, E. Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease. Drugs 81(17), 1969–1981 (2021).",
        "journal-title": "Drugs"
      },
      {
        "issue": "41",
        "key": "31777_CR22",
        "doi-asserted-by": "publisher",
        "first-page": "14420",
        "DOI": "10.1002/anie.201907729",
        "volume": "58",
        "author": "FH Arnold",
        "year": "2019",
        "unstructured": "Arnold, F. H. Innovation by evolution: Bringing new chemistry to life (Nobel Lecture). Angew. Chem. Int. Ed. Engl. 58(41), 14420–14426 (2019).",
        "journal-title": "Angew. Chem. Int. Ed. Engl."
      },
      {
        "issue": "2",
        "key": "31777_CR23",
        "doi-asserted-by": "publisher",
        "first-page": "319",
        "DOI": "10.1016/j.jmb.2004.01.035",
        "volume": "337",
        "author": "SC Garman",
        "year": "2004",
        "unstructured": "Garman, S. C. & Garboczi, D. N. The molecular defect leading to Fabry disease: Structure of human alpha-galactosidase. J. Mol. Biol. 337(2), 319–335 (2004).",
        "journal-title": "J. Mol. Biol."
      },
      {
        "issue": "1",
        "key": "31777_CR24",
        "doi-asserted-by": "publisher",
        "first-page": "184",
        "DOI": "10.1016/S0021-9258(17)38286-8",
        "volume": "253",
        "author": "JW Kusiak",
        "year": "1978",
        "unstructured": "Kusiak, J. W., Quirk, J. M. & Brady, R. O. Purification and properties of the two major isozymes of alpha-galactosidase from human placenta. J. Biol. Chem. 253(1), 184–190 (1978).",
        "journal-title": "J. Biol. Chem."
      },
      {
        "issue": "7",
        "key": "31777_CR25",
        "doi-asserted-by": "publisher",
        "first-page": "3363",
        "DOI": "10.4049/jimmunol.160.7.3363",
        "volume": "160",
        "author": "S Southwood",
        "year": "1998",
        "unstructured": "Southwood, S. et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160(7), 3363–3373 (1998).",
        "journal-title": "J. Immunol."
      },
      {
        "issue": "12",
        "key": "31777_CR26",
        "doi-asserted-by": "publisher",
        "first-page": "1521",
        "DOI": "10.1016/j.chembiol.2011.10.012",
        "volume": "18",
        "author": "AI Guce",
        "year": "2011",
        "unstructured": "Guce, A. I. et al. The molecular basis of pharmacological chaperoning in human alpha-galactosidase. Chem. Biol. 18(12), 1521–1526 (2011).",
        "journal-title": "Chem. Biol."
      },
      {
        "issue": "5",
        "key": "31777_CR27",
        "doi-asserted-by": "publisher",
        "first-page": "F1015",
        "DOI": "10.1152/ajprenal.00283.2016",
        "volume": "311",
        "author": "EM Pereira",
        "year": "2016",
        "unstructured": "Pereira, E. M. et al. Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology. Am. J. Physiol. Renal. Physiol. 311(5), F1015–F1024 (2016).",
        "journal-title": "Am. J. Physiol. Renal. Physiol."
      },
      {
        "issue": "17",
        "key": "31777_CR28",
        "doi-asserted-by": "publisher",
        "first-page": "1793",
        "DOI": "10.4155/bio-2016-0116",
        "volume": "8",
        "author": "P Provencal",
        "year": "2016",
        "unstructured": "Provencal, P. et al. Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry. Bioanalysis 8(17), 1793–1807 (2016).",
        "journal-title": "Bioanalysis"
      },
      {
        "issue": "3",
        "key": "31777_CR29",
        "doi-asserted-by": "publisher",
        "first-page": "202",
        "DOI": "10.1038/nrm1050",
        "volume": "4",
        "author": "P Ghosh",
        "year": "2003",
        "unstructured": "Ghosh, P., Dahms, N. M. & Kornfeld, S. Mannose 6-phosphate receptors: New twists in the tale. Nat. Rev. Mol. Cell Biol. 4(3), 202–212 (2003).",
        "journal-title": "Nat. Rev. Mol. Cell Biol."
      },
      {
        "issue": "2–3",
        "key": "31777_CR30",
        "doi-asserted-by": "publisher",
        "first-page": "229",
        "DOI": "10.1089/rej.2009.0920",
        "volume": "13",
        "author": "JH Grubb",
        "year": "2010",
        "unstructured": "Grubb, J. H., Vogler, C. & Sly, W. S. New strategies for enzyme replacement therapy for lysosomal storage diseases. Rejuvenation Res. 13(2–3), 229–236 (2010).",
        "journal-title": "Rejuvenation Res."
      },
      {
        "issue": "1–2",
        "key": "31777_CR31",
        "doi-asserted-by": "publisher",
        "first-page": "153",
        "DOI": "10.1016/j.ymgme.2018.07.009",
        "volume": "125",
        "author": "H Morimoto",
        "year": "2018",
        "unstructured": "Morimoto, H. et al. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease. Mol. Genet. Metab. 125(1–2), 153–160 (2018).",
        "journal-title": "Mol. Genet. Metab."
      },
      {
        "issue": "5",
        "key": "31777_CR32",
        "doi-asserted-by": "publisher",
        "first-page": "569",
        "DOI": "10.1016/j.ajhg.2009.09.016",
        "volume": "85",
        "author": "Y Tajima",
        "year": "2009",
        "unstructured": "Tajima, Y. et al. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 85(5), 569–580 (2009).",
        "journal-title": "Am. J. Hum. Genet."
      },
      {
        "issue": "2",
        "key": "31777_CR33",
        "doi-asserted-by": "publisher",
        "first-page": "277",
        "DOI": "10.1080/21645515.2019.1703453",
        "volume": "16",
        "author": "C Kruiswijk",
        "year": "2020",
        "unstructured": "Kruiswijk, C. et al. In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance. Hum. Vaccin. Immunother. 16(2), 277–285 (2020).",
        "journal-title": "Hum. Vaccin. Immunother."
      },
      {
        "key": "31777_CR34",
        "doi-asserted-by": "publisher",
        "first-page": "698",
        "DOI": "10.3389/fimmu.2020.00698",
        "volume": "11",
        "author": "AC Karle",
        "year": "2020",
        "unstructured": "Karle, A. C. Applying MAPPs assays to assess drug immunogenicity. Front. Immunol. 11, 698 (2020).",
        "journal-title": "Front. Immunol."
      },
      {
        "issue": "9",
        "key": "31777_CR35",
        "doi-asserted-by": "publisher",
        "first-page": "733",
        "DOI": "10.1080/14789450.2018.1521279",
        "volume": "15",
        "author": "V Quarmby",
        "year": "2018",
        "unstructured": "Quarmby, V., Phung, Q. T. & Lill, J. R. MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena. Expert Rev. Proteom. 15(9), 733–748 (2018).",
        "journal-title": "Expert Rev. Proteom."
      },
      {
        "key": "31777_CR36",
        "doi-asserted-by": "publisher",
        "first-page": "1301",
        "DOI": "10.3389/fimmu.2020.01301",
        "volume": "11",
        "author": "V Jawa",
        "year": "2020",
        "unstructured": "Jawa, V. et al. T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation-updated consensus and review 2020. Front. Immunol. 11, 1301 (2020).",
        "journal-title": "Front. Immunol."
      },
      {
        "issue": "8",
        "key": "31777_CR37",
        "doi-asserted-by": "publisher",
        "first-page": "e0159328",
        "DOI": "10.1371/journal.pone.0159328",
        "volume": "11",
        "author": "MK Joubert",
        "year": "2016",
        "unstructured": "Joubert, M. K. et al. Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics. PLoS One 11(8), e0159328 (2016).",
        "journal-title": "PLoS One"
      },
      {
        "issue": "5",
        "key": "31777_CR38",
        "doi-asserted-by": "publisher",
        "first-page": "416",
        "DOI": "10.1093/ckj/sfs119",
        "volume": "5",
        "author": "S Al-Salam",
        "year": "2012",
        "unstructured": "Al-Salam, S. et al. Renal variant of Fabry disease with sporadic GLA gene mutation: Role of early renal biopsy. Clin. Kidney J. 5(5), 416–419 (2012).",
        "journal-title": "Clin. Kidney J."
      },
      {
        "issue": "2",
        "key": "31777_CR39",
        "doi-asserted-by": "publisher",
        "first-page": "239",
        "DOI": "10.1007/s10545-017-0127-2",
        "volume": "41",
        "author": "FJ Alharbi",
        "year": "2018",
        "unstructured": "Alharbi, F. J. et al. Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease. J. Inherit. Metab. Dis. 41(2), 239–247 (2018).",
        "journal-title": "J. Inherit. Metab. Dis."
      },
      {
        "issue": "2",
        "key": "31777_CR40",
        "doi-asserted-by": "publisher",
        "first-page": "157",
        "DOI": "10.1016/j.ymgme.2017.05.001",
        "volume": "121",
        "author": "M Arends",
        "year": "2017",
        "unstructured": "Arends, M. et al. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol. Genet. Metab. 121(2), 157–161 (2017).",
        "journal-title": "Mol. Genet. Metab."
      },
      {
        "key": "31777_CR41",
        "volume-title": "Fabry Disease: Perspectives from 5 Years of FOS",
        "author": "P Deegan",
        "year": "2006",
        "unstructured": "Deegan, P. et al. Fabry disease in females: clinical characteristics and effects of enzyme replacement therapy. In Fabry Disease: Perspectives from 5 Years of FOS (eds Mehta, A. et al.) (Oxford PharmaGenesis, 2006)."
      },
      {
        "key": "31777_CR42",
        "volume-title": "The Metabolic and Molecular Basis of Inherited Disease",
        "author": "RJ Desnick",
        "year": "2001",
        "unstructured": "Desnick, R. J. & Ioannou, Y. A. Eng, a-Galactosidase A deficiency: Fabry Disease. In The Metabolic and Molecular Basis of Inherited Disease (eds Scriver, C. R. et al.) (McGraw-Hill, 2001)."
      },
      {
        "issue": "8",
        "key": "31777_CR43",
        "doi-asserted-by": "publisher",
        "first-page": "1890",
        "DOI": "10.1038/s41436-019-0436-y",
        "volume": "21",
        "author": "JJ Juang",
        "year": "2019",
        "unstructured": "Juang, J. J. et al. Fabry disease cardiac variant IVS4+919 G>A is associated with multiple cardiac gene variants in patients with severe cardiomyopathy and fatal arrhythmia. Genet. Med. 21(8), 1890–1891 (2019).",
        "journal-title": "Genet. Med."
      },
      {
        "key": "31777_CR44",
        "doi-asserted-by": "publisher",
        "first-page": "13",
        "DOI": "10.1023/A:1012447102358",
        "volume": "24 Suppl 2",
        "author": "KD MacDermot",
        "year": "2001",
        "unstructured": "MacDermot, K. D., Holmes, A. & Miners, A. H. Natural history of Fabry disease in affected males and obligate carrier females. J. Inherit. Metab. Dis. 24 Suppl 2, 13–14 (2001) (discussion 11–2).",
        "journal-title": "J. Inherit. Metab. Dis."
      },
      {
        "key": "31777_CR45",
        "doi-asserted-by": "publisher",
        "first-page": "43",
        "DOI": "10.1016/j.ymgmr.2018.01.006",
        "volume": "15",
        "author": "M Sugarman",
        "year": "2018",
        "unstructured": "Sugarman, M., Choudhury, J. & Jovanovic, A. An atypical p. N215S variant of Fabry disease with end-stage renal failure. Mol. Genet. Metab. Rep. 15, 43–45 (2018).",
        "journal-title": "Mol. Genet. Metab. Rep."
      },
      {
        "issue": "1",
        "key": "31777_CR46",
        "doi-asserted-by": "publisher",
        "first-page": "34",
        "DOI": "10.1097/GIM.0b013e31802d8321",
        "volume": "9",
        "author": "RY Wang",
        "year": "2007",
        "unstructured": "Wang, R. Y. et al. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med. 9(1), 34–45 (2007).",
        "journal-title": "Genet. Med."
      },
      {
        "issue": "5",
        "key": "31777_CR47",
        "doi-asserted-by": "publisher",
        "first-page": "1630",
        "DOI": "10.1021/acs.bioconjchem.8b00133",
        "volume": "29",
        "author": "I Ruderfer",
        "year": "2018",
        "unstructured": "Ruderfer, I. et al. Development and analytical characterization of Pegunigalsidase Alfa, a chemically cross-linked plant recombinant human alpha-galactosidase—a for treatment of Fabry disease. Bioconjug. Chem. 29(5), 1630–1639 (2018).",
        "journal-title": "Bioconjug. Chem."
      },
      {
        "issue": "2",
        "key": "31777_CR48",
        "doi-asserted-by": "publisher",
        "first-page": "259",
        "DOI": "10.1016/j.ymgme.2014.08.002",
        "volume": "114",
        "author": "T Kizhner",
        "year": "2015",
        "unstructured": "Kizhner, T. et al. Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase—a enzyme for treatment of Fabry disease. Mol. Genet. Metab. 114(2), 259–267 (2015).",
        "journal-title": "Mol. Genet. Metab."
      },
      {
        "issue": "9",
        "key": "31777_CR49",
        "doi-asserted-by": "publisher",
        "first-page": "1401",
        "DOI": "10.1002/pro.2719",
        "volume": "24",
        "author": "H Qiu",
        "year": "2015",
        "unstructured": "Qiu, H. et al. Impact of cysteine variants on the structure, activity, and stability of recombinant human alpha-galactosidase A. Protein Sci. 24(9), 1401–1411 (2015).",
        "journal-title": "Protein Sci."
      },
      {
        "key": "31777_CR50",
        "doi-asserted-by": "publisher",
        "first-page": "105710",
        "DOI": "10.1016/j.pep.2020.105710",
        "volume": "175",
        "author": "ES Stokes",
        "year": "2020",
        "unstructured": "Stokes, E. S., Gilchrist, M. L. & Calhoun, D. H. Prediction of improved therapeutics for Fabry disease patients generated by mutagenesis of the alpha-galactosidase A active site, dimer interface, and glycosylation region. Protein Expr. Purif. 175, 105710 (2020).",
        "journal-title": "Protein Expr. Purif."
      },
      {
        "issue": "2",
        "key": "31777_CR51",
        "doi-asserted-by": "publisher",
        "first-page": "e0118341",
        "DOI": "10.1371/journal.pone.0118341",
        "volume": "10",
        "author": "M Meghdari",
        "year": "2015",
        "unstructured": "Meghdari, M. et al. Carboxyl-terminal truncations alter the activity of the human alpha-galactosidase A. PLoS One 10(2), e0118341 (2015).",
        "journal-title": "PLoS One"
      },
      {
        "issue": "2",
        "key": "31777_CR52",
        "doi-asserted-by": "publisher",
        "first-page": "293",
        "DOI": "10.1007/s10545-015-9886-9",
        "volume": "39",
        "author": "JS Shen",
        "year": "2016",
        "unstructured": "Shen, J. S. et al. Mannose receptor-mediated delivery of moss-made alpha-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. J. Inherit. Metab. Dis. 39(2), 293–303 (2016).",
        "journal-title": "J. Inherit. Metab. Dis."
      },
      {
        "issue": "1",
        "key": "31777_CR53",
        "doi-asserted-by": "publisher",
        "first-page": "8730",
        "DOI": "10.1038/s41598-018-26913-4",
        "volume": "8",
        "author": "JY Kang",
        "year": "2018",
        "unstructured": "Kang, J. Y. et al. Lysosomal targeting enhancement by conjugation of glycopeptides containing mannose-6-phosphate glycans derived from glyco-engineered yeast. Sci. Rep. 8(1), 8730 (2018).",
        "journal-title": "Sci. Rep."
      },
      {
        "issue": "6",
        "key": "31777_CR54",
        "doi-asserted-by": "publisher",
        "first-page": "954",
        "DOI": "10.1038/mt.2009.37",
        "volume": "17",
        "author": "Y Zhu",
        "year": "2009",
        "unstructured": "Zhu, Y. et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol. Ther. 17(6), 954–963 (2009).",
        "journal-title": "Mol. Ther."
      },
      {
        "issue": "1",
        "key": "31777_CR55",
        "doi-asserted-by": "publisher",
        "first-page": "1785",
        "DOI": "10.1038/s41467-019-09809-3",
        "volume": "10",
        "author": "W Tian",
        "year": "2019",
        "unstructured": "Tian, W. et al. The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells. Nat. Commun. 10(1), 1785 (2019).",
        "journal-title": "Nat. Commun."
      },
      {
        "key": "31777_CR56",
        "doi-asserted-by": "publisher",
        "first-page": "AB063",
        "DOI": "10.21037/atm.2017.s063",
        "volume": "5",
        "author": "YR Chen",
        "year": "2017",
        "unstructured": "Chen, Y. R. Development of a fusion protein combined alpha-galactosidase A and insulin-like growth factor 2 for treatment of Fabry disease. Ann. Transl. Med. 5, AB063 (2017).",
        "journal-title": "Ann. Transl. Med."
      },
      {
        "issue": "5–6",
        "key": "31777_CR57",
        "doi-asserted-by": "publisher",
        "first-page": "216",
        "DOI": "10.2119/molmed.2009.00163",
        "volume": "16",
        "author": "K Higuchi",
        "year": "2010",
        "unstructured": "Higuchi, K. et al. Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice. Mol. Med. 16(5–6), 216–221 (2010).",
        "journal-title": "Mol. Med."
      },
      {
        "key": "31777_CR58",
        "first-page": "20",
        "volume": "20",
        "author": "U Feldt-Rasmussen",
        "year": "2020",
        "unstructured": "Feldt-Rasmussen, U. et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol. Genet. Metab. 20, 20 (2020).",
        "journal-title": "Mol. Genet. Metab."
      },
      {
        "issue": "4",
        "key": "31777_CR59",
        "doi-asserted-by": "publisher",
        "first-page": "288",
        "DOI": "10.1136/jmedgenet-2016-104178",
        "volume": "54",
        "author": "DA Hughes",
        "year": "2017",
        "unstructured": "Hughes, D. A. et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J. Med. Genet. 54(4), 288–296 (2017).",
        "journal-title": "J. Med. Genet."
      },
      {
        "issue": "17",
        "key": "31777_CR60",
        "doi-asserted-by": "publisher",
        "first-page": "1671",
        "DOI": "10.1056/NEJMoa0904377",
        "volume": "361",
        "author": "P Simioni",
        "year": "2009",
        "unstructured": "Simioni, P. et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N. Engl. J. Med. 361(17), 1671–1675 (2009).",
        "journal-title": "N. Engl. J. Med."
      },
      {
        "issue": "23",
        "key": "31777_CR61",
        "doi-asserted-by": "publisher",
        "first-page": "4517",
        "DOI": "10.1182/blood-2012-05-432591",
        "volume": "120",
        "author": "A Cantore",
        "year": "2012",
        "unstructured": "Cantore, A. et al. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood 120(23), 4517–4520 (2012).",
        "journal-title": "Blood"
      },
      {
        "issue": "23",
        "key": "31777_CR62",
        "doi-asserted-by": "publisher",
        "first-page": "2215",
        "DOI": "10.1056/NEJMoa1708538",
        "volume": "377",
        "author": "LA George",
        "year": "2017",
        "unstructured": "George, L. A. et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N. Engl. J. Med. 377(23), 2215–2227 (2017).",
        "journal-title": "N. Engl. J. Med."
      },
      {
        "key": "31777_CR63",
        "unstructured": "Baidyaroy, D., L. Clark, & L.M. Newman, Recombinant Thermoascus auranticus β-glucosidase variants for production of fermentable sugars from cellulosic biomass, in USPTO.gov, USPTO, Editor. 2011, Codexis, Inc.: USA."
      },
      {
        "issue": "5",
        "key": "31777_CR64",
        "first-page": "528",
        "volume": "8",
        "author": "RM Horton",
        "year": "1990",
        "unstructured": "Horton, R. M. et al. Gene splicing by overlap extension: Tailor-made genes using the polymerase chain reaction. Biotechniques 8(5), 528–535 (1990).",
        "journal-title": "Biotechniques"
      },
      {
        "issue": "5–6",
        "key": "31777_CR65",
        "doi-asserted-by": "publisher",
        "first-page": "339",
        "DOI": "10.1007/BF00340712",
        "volume": "16",
        "author": "RH Schiestl",
        "year": "1989",
        "unstructured": "Schiestl, R. H. & Gietz, R. D. High efficiency transformation of intact yeast cells using single stranded nucleic acids as a carrier. Curr. Genet. 16(5–6), 339–346 (1989).",
        "journal-title": "Curr. Genet."
      },
      {
        "issue": "8",
        "key": "31777_CR66",
        "doi-asserted-by": "publisher",
        "first-page": "2727",
        "DOI": "10.4049/jimmunol.1701764",
        "volume": "200",
        "author": "T Singh",
        "year": "2018",
        "unstructured": "Singh, T. et al. Epitope-binding characteristics for risk versus protective DRB1 alleles for visceral leishmaniasis. J. Immunol. 200(8), 2727–2737 (2018).",
        "journal-title": "J. Immunol."
      },
      {
        "issue": "2",
        "key": "31777_CR67",
        "doi-asserted-by": "publisher",
        "first-page": "499",
        "DOI": "10.1016/j.pep.2004.07.005",
        "volume": "37",
        "author": "K Yasuda",
        "year": "2004",
        "unstructured": "Yasuda, K. et al. Efficient and rapid purification of recombinant human alpha-galactosidase A by affinity column chromatography. Protein Expr. Purif. 37(2), 499–506 (2004).",
        "journal-title": "Protein Expr. Purif."
      },
      {
        "key": "31777_CR68",
        "doi-asserted-by": "publisher",
        "first-page": "2",
        "DOI": "10.3390/pharmaceutics10020069",
        "volume": "10",
        "author": "SH Shin",
        "year": "2018",
        "unstructured": "Shin, S. H. et al. A liquid chromatography-quadrupole-time-of-flight mass spectrometric assay for the quantification of fabry disease biomarker globotriaosylceramide (GB3) in Fabry model mouse. Pharmaceutics 10, 2 (2018).",
        "journal-title": "Pharmaceutics"
      },
      {
        "issue": "6",
        "key": "31777_CR69",
        "doi-asserted-by": "publisher",
        "first-page": "2540",
        "DOI": "10.1073/pnas.94.6.2540",
        "volume": "94",
        "author": "T Ohshima",
        "year": "1997",
        "unstructured": "Ohshima, T. et al. alpha-Galactosidase A deficient mice: A model of Fabry disease. Proc. Natl. Acad. Sci. USA 94(6), 2540–2544 (1997).",
        "journal-title": "Proc. Natl. Acad. Sci. USA"
      },
      {
        "issue": "9",
        "key": "31777_CR70",
        "doi-asserted-by": "publisher",
        "first-page": "1742",
        "DOI": "10.1194/jlr.M017178",
        "volume": "52",
        "author": "B Durant",
        "year": "2011",
        "unstructured": "Durant, B. et al. Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice. J. Lipid Res. 52(9), 1742–1746 (2011).",
        "journal-title": "J. Lipid Res."
      }
    ],
    "container-title": [
      "Scientific Reports"
    ],
    "original-title": [],
    "language": "en",
    "link": [
      {
        "URL": "https://www.nature.com/articles/s41598-023-31777-4.pdf",
        "content-type": "application/pdf",
        "content-version": "vor",
        "intended-application": "text-mining"
      },
      {
        "URL": "https://www.nature.com/articles/s41598-023-31777-4",
        "content-type": "text/html",
        "content-version": "vor",
        "intended-application": "text-mining"
      },
      {
        "URL": "https://www.nature.com/articles/s41598-023-31777-4.pdf",
        "content-type": "application/pdf",
        "content-version": "vor",
        "intended-application": "similarity-checking"
      }
    ],
    "deposited": {
      "date-parts": [
        [
          2023,
          12,
          9
        ]
      ],
      "date-time": "2023-12-09T13:18:12Z",
      "timestamp": 1702127892000
    },
    "score": 1,
    "resource": {
      "primary": {
        "URL": "https://www.nature.com/articles/s41598-023-31777-4"
      }
    },
    "subtitle": [],
    "short-title": [],
    "issued": {
      "date-parts": [
        [
          2023,
          3,
          23
        ]
      ]
    },
    "references-count": 70,
    "journal-issue": {
      "issue": "1",
      "published-online": {
        "date-parts": [
          [
            2023,
            12
          ]
        ]
      }
    },
    "alternative-id": [
      "31777"
    ],
    "URL": "https://doi.org/10.1038/s41598-023-31777-4",
    "relation": {},
    "ISSN": [
      "2045-2322"
    ],
    "issn-type": [
      {
        "value": "2045-2322",
        "type": "electronic"
      }
    ],
    "subject": [],
    "published": {
      "date-parts": [
        [
          2023,
          3,
          23
        ]
      ]
    },
    "assertion": [
      {
        "value": "16 August 2022",
        "order": 1,
        "name": "received",
        "label": "Received",
        "group": {
          "name": "ArticleHistory",
          "label": "Article History"
        }
      },
      {
        "value": "17 March 2023",
        "order": 2,
        "name": "accepted",
        "label": "Accepted",
        "group": {
          "name": "ArticleHistory",
          "label": "Article History"
        }
      },
      {
        "value": "23 March 2023",
        "order": 3,
        "name": "first_online",
        "label": "First Online",
        "group": {
          "name": "ArticleHistory",
          "label": "Article History"
        }
      },
      {
        "value": "All current Codexis employees are shareholders of the company.",
        "order": 1,
        "name": "Ethics",
        "group": {
          "name": "EthicsHeading",
          "label": "Competing interests"
        }
      }
    ],
    "article-number": "4748"
  },
  "semanticscholar": {},
  "unpaywall": {
    "doi": "10.1038/s41598-023-31777-4",
    "doi_url": "https://doi.org/10.1038/s41598-023-31777-4",
    "title": "Optimizing human α-galactosidase for treatment of Fabry disease",
    "genre": "journal-article",
    "is_paratext": false,
    "published_date": "2023-03-23",
    "year": 2023,
    "journal_name": "Scientific Reports",
    "journal_issns": "2045-2322",
    "journal_issn_l": "2045-2322",
    "journal_is_oa": true,
    "journal_is_in_doaj": true,
    "publisher": "Springer Science and Business Media LLC",
    "is_oa": true,
    "oa_status": "gold",
    "has_repository_copy": true,
    "best_oa_location": {
      "url": "https://www.nature.com/articles/s41598-023-31777-4.pdf",
      "url_for_pdf": "https://www.nature.com/articles/s41598-023-31777-4.pdf",
      "url_for_landing_page": "https://doi.org/10.1038/s41598-023-31777-4",
      "evidence": "deprecated",
      "license": "cc-by",
      "version": "publishedVersion",
      "host_type": "publisher",
      "is_best": true,
      "pmh_id": null,
      "endpoint_id": null,
      "repository_institution": null,
      "oa_date": "2023-03-23",
      "updated": "deprecated"
    },
    "first_oa_location": {
      "url": "https://www.nature.com/articles/s41598-023-31777-4.pdf",
      "url_for_pdf": "https://www.nature.com/articles/s41598-023-31777-4.pdf",
      "url_for_landing_page": "https://doi.org/10.1038/s41598-023-31777-4",
      "evidence": "deprecated",
      "license": "cc-by",
      "version": "publishedVersion",
      "host_type": "publisher",
      "is_best": true,
      "pmh_id": null,
      "endpoint_id": null,
      "repository_institution": null,
      "oa_date": "2023-03-23",
      "updated": "deprecated"
    },
    "oa_locations": [
      {
        "url": "https://www.nature.com/articles/s41598-023-31777-4.pdf",
        "url_for_pdf": "https://www.nature.com/articles/s41598-023-31777-4.pdf",
        "url_for_landing_page": "https://doi.org/10.1038/s41598-023-31777-4",
        "evidence": "deprecated",
        "license": "cc-by",
        "version": "publishedVersion",
        "host_type": "publisher",
        "is_best": true,
        "pmh_id": null,
        "endpoint_id": null,
        "repository_institution": null,
        "oa_date": "2023-03-23",
        "updated": "deprecated"
      },
      {
        "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/10036536",
        "url_for_pdf": null,
        "url_for_landing_page": "https://www.ncbi.nlm.nih.gov/pmc/articles/10036536",
        "evidence": "deprecated",
        "license": "other-oa",
        "version": "submittedVersion",
        "host_type": "repository",
        "is_best": false,
        "pmh_id": "oai:pubmedcentral.nih.gov:10036536",
        "endpoint_id": "daaf77eacc58eec31bb",
        "repository_institution": "PubMed Central",
        "oa_date": "2023-03-23",
        "updated": "deprecated"
      }
    ],
    "oa_locations_embargoed": [],
    "data_standard": 2,
    "z_authors": [
      {
        "author_position": "first",
        "raw_author_name": "William C. Hallows",
        "is_corresponding": true,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Kristen Skvorak",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Nick Agard",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Nikki Kruse",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Xiyun Zhang",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Yu Zhu",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Rachel C. Botham",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Chinping Chng",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Charu Shukla",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Jessica Lao",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Mathew Miller",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Antoinette Sero",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Judy Viduya",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Moulay Hicham Alaoui Ismaili",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Kerryn McCluskie",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Raphael Schiffmann",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Institute of Metabolic Disease, Baylor Research Institute, Dallas, TX, 75246, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Adam P. Silverman",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      },
      {
        "author_position": "additional",
        "raw_author_name": "Jin-Song Shen",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Institute of Metabolic Disease, Baylor Research Institute, Dallas, TX, 75246, USA"
        ]
      },
      {
        "author_position": "last",
        "raw_author_name": "Gjalt W. Huisman",
        "is_corresponding": false,
        "raw_affiliation_strings": [
          "Codexis Inc.,, 200 Penobscot Drive, Redwood City, CA, 94063, USA"
        ]
      }
    ],
    "updated": "2025-07-30T00:59:52Z"
  },
  "oa_pdf_url": "https://www.nature.com/articles/s41598-023-31777-4.pdf",
  "oa_license": "cc-by",
  "doi": "10.1038/s41598-023-31777-4",
  "pillar_primary": "Design & Engineering",
  "fallback_search": false,
  "raw_citation": "Optimizing human α-galactosidase for treatment of Fabry disease William C Hallows Kristen Skvorak Nick Agard Nikki Kruse Xiyun Zhang Yu Zhu Rachel C Botham Chinping Chng Charu Shukla Jessica Lao Mathew Miller Antoinette Sero Judy Viduya Moulay Hicham Alaoui Ismaili Kerryn Mccluskie Raphael Schiffmann Adam P Silverman Jin-Song Shen Gjalt W Huisman 10.1038/s41598-023-31777-4 Scientific Reports Sci Rep 2045-2322 13 1 4748 2023 Springer Science and Business Media LLC"
}